Recruiting × INDUSTRY × Esophageal Neoplasms × Clear all
NCT05581004 2026-04-15

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Genentech, Inc.

Phase 1 Recruiting
450 enrolled
NCT05005403 2026-04-13

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

AbbVie

Phase 1 Recruiting
694 enrolled
NCT07124000 2026-03-31

DP-04

AstraZeneca

Recruiting
100 enrolled
NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
NCT06910657 2026-03-02

IDOV-Immune for Advanced Solid Tumors

ViroMissile, Inc.

Phase 1 Recruiting
78 enrolled
NCT06128551 2026-02-10

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Revolution Medicines, Inc.

Phase 1/2 Recruiting
534 enrolled
NCT05983432 2026-01-29

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

SystImmune Inc.

Phase 1 Recruiting
470 enrolled
NCT06172478 2026-01-28

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Daiichi Sankyo

Phase 2 Recruiting
740 enrolled
NCT05366881 2026-01-20

CAMPERR

Adela, Inc

Recruiting
7,000 enrolled
NCT03556228 2025-12-11

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

VM Oncology, LLC

Phase 1/2 Recruiting
242 enrolled
NCT06943521 2025-12-11

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Tanabe Pharma America, Inc.

Phase 1/2 Recruiting
27 enrolled
NCT03452774 2025-10-28

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio, Inc.

Recruiting
50,000 enrolled
NCT05086692 2025-07-09

ABILITY-1

Medicenna Therapeutics, Inc.

Phase 1/2 Recruiting
115 enrolled
NCT05592626 2025-07-09

START-001

Marengo Therapeutics, Inc.

Phase 1/2 Recruiting
365 enrolled
NCT06239194 2025-06-22

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

ModeX Therapeutics, An OPKO Health Company

Phase 1/2 Recruiting
115 enrolled